Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Clinical Science Track

Clinical study of 68Ga labeled homologue of gastrin-releasing peptide for PET/CT imaging of patient with prostate cancer

Xiaowei Ma, Shengjun Wang, Yao Sun, Yongheng Gao, Daliang Liu, Fei Kang, Weidong Yang, Zhen Cheng and Jing Wang
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1557;
Xiaowei Ma
2Department of Nuclear Medicine Xijing Hospital Xi'an China
1Molecular Imaging Program at Stanford (MIPS), Bio-X Program, and Department of Radiology Stanford University Stanford CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shengjun Wang
2Department of Nuclear Medicine Xijing Hospital Xi'an China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao Sun
1Molecular Imaging Program at Stanford (MIPS), Bio-X Program, and Department of Radiology Stanford University Stanford CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongheng Gao
2Department of Nuclear Medicine Xijing Hospital Xi'an China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daliang Liu
2Department of Nuclear Medicine Xijing Hospital Xi'an China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Kang
2Department of Nuclear Medicine Xijing Hospital Xi'an China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weidong Yang
2Department of Nuclear Medicine Xijing Hospital Xi'an China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhen Cheng
1Molecular Imaging Program at Stanford (MIPS), Bio-X Program, and Department of Radiology Stanford University Stanford CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Wang
2Department of Nuclear Medicine Xijing Hospital Xi'an China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1557

Objectives Gastrin-releasing peptide receptors (GRPRs) are highly overexpressed in 63-100% of human prostate cancers (PCs). In this study, we investigated a 68Ga labeled amphibian homologue of mammalian gastrin-releasing peptide 68Ga-RM1 that targets GRPRs for PCs detection of patients.

Methods A total of 7 pre-surgical men patients (mean age ± SD: 65.6±9.4 year-old) with newly diagnosed and biopsy-proven PCs were subjected to 68Ga-RM1 positron emission tomography (PET) study. The prostate-specific antigen (PSA) levels of all patients were examined. PET/CT imaging started at 40-50 minutes after injection of 111-142 MBq (mean±SD: 127±6 MBq) of 68Ga-RM1 (purity >98%) using a PET/CT scanner (Biograph 40, Siemens). Quantitative assessment of 68Ga-RM1 uptake was performed by analysis of maximum standardized uptake value (SUVmax) and mean SUV (SUVmean) of tumor region and background in normal tissues. Subsequently, tumor to background ratios were calculated.

Results All patients had significant abnormal PSA levels (mean±SD: 19.5±13.1 ng/ml) and Gleason scores (6-9). The PET/CT images showed high physiologic uptake in the pancreas (SUVmean: 11.67±3.85) and quick renal clearance. Among the 7 patients, high and specific uptake in primary cancer lesions were found. The SUVmean and SUVmax of tumor region is 4.22±1.33 and 4.64±2.53. One patient (1/7) had 3 visible positive lymph nodes in the abdomen and one patient (1/7) had 4 metastases in bone. Quantitative assessment revealed excellent contrast between tumor lesions and normal tissues. Median tumor to background ratios were 15.29 (9.27-26.42).

Conclusions Preliminary clinical data indicate that the use of 68Ga-RM1 in patients with prostate cancer is safe and feasible. 68Ga-RM1 could be an optional imaging probe for the imaging of PCs. However, further study on the relationship between PSA level and SUV of tumor, the comparison with other PCs targeting probes should be performed in future. Research Support: This work was supported, in part, by the Key Program of National Natural Science Foundation of China (Grant No. 81230033) and the Office of Science (BER), U.S. Department of Energy (DE-SC0008397).

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical study of 68Ga labeled homologue of gastrin-releasing peptide for PET/CT imaging of patient with prostate cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Clinical study of 68Ga labeled homologue of gastrin-releasing peptide for PET/CT imaging of patient with prostate cancer
Xiaowei Ma, Shengjun Wang, Yao Sun, Yongheng Gao, Daliang Liu, Fei Kang, Weidong Yang, Zhen Cheng, Jing Wang
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1557;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Clinical study of 68Ga labeled homologue of gastrin-releasing peptide for PET/CT imaging of patient with prostate cancer
Xiaowei Ma, Shengjun Wang, Yao Sun, Yongheng Gao, Daliang Liu, Fei Kang, Weidong Yang, Zhen Cheng, Jing Wang
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1557;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology, Clinical Science Track

  • Clinical management and outcomes in differentiated thyroid cancer patients with positive postoperative-stimulated thyroglobulin antibody and undetectable postoperative-stimulated thyroglobulin at initial 131I ablation after total thyroidectomy
  • Clinical value of 68Ga-DOTATATE PET/CT in the evaluation of recurrent medullary thyroid cancer patients.
  • The diagnostic performance and added value of 18F-NaF PET/CT in the detection of bone metastases in patients with nasopharyngeal carcinoma
Show more Oncology, Clinical Science Track

MTA I: Prostate/GU Posters

  • Radiographic and laboratory assessment of bone metastases in castration-resistant prostate cancer patients undergoing Radium-223 dichloride therapy
  • Ga-68-PSMA11 PET/CT vs. multi-parametric MRI for primary prostate cancer T-staging
  • Initial experience with 11C-acetate PET/CT in management of recurrent prostate cancer under an Expanded Access IND.
Show more MTA I: Prostate/GU Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire